Published in Oncotarget on July 30, 2014
Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways. Oncotarget (2016) 0.78
Waltonitone inhibits proliferation of hepatoma cells and tumorigenesis via FXR-miR-22-CCNA2 signaling pathway. Oncotarget (2016) 0.76
Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling. Gastroenterology (2017) 0.75
Celastrol increases osteosarcoma cell lysis by γδ T cells through up-regulation of death receptors. Oncotarget (2016) 0.75
Celastrol: A Spectrum of Treatment Opportunities in Chronic Diseases. Front Med (Lausanne) (2017) 0.75
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer (2010) 90.16
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30
Hepatocellular carcinoma. Lancet (2012) 18.09
Multimodal fast optical interrogation of neural circuitry. Nature (2007) 14.68
HSP90 and the chaperoning of cancer. Nat Rev Cancer (2005) 11.98
Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest (2008) 10.74
Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer (2010) 6.81
Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature (2007) 6.56
Molecular targeted therapies in hepatocellular carcinoma. Hepatology (2008) 6.16
Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther (2008) 5.78
Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology (2008) 4.03
Hsp90 molecular chaperone inhibitors: are we there yet? Clin Cancer Res (2012) 4.01
Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis (2007) 3.75
Murine models to evaluate novel and conventional therapeutic strategies for cancer. Am J Pathol (2007) 3.03
Targeted therapies for hepatocellular carcinoma. Gastroenterology (2011) 2.85
Patient-derived tumor xenografts: transforming clinical samples into mouse models. Cancer Res (2013) 2.74
Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. J Hepatol (2009) 2.42
The Mechanism of Hsp90 regulation by the protein kinase-specific cochaperone p50(cdc37). Cell (2004) 2.36
Update on Hsp90 inhibitors in clinical trial. Curr Top Med Chem (2009) 2.34
mTOR and P70 S6 kinase expression in primary liver neoplasms. Clin Cancer Res (2004) 2.14
A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells. Mol Cancer Ther (2008) 2.07
Targeted inhibition of the extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) in the treatment of hepatocellular carcinoma. Mol Cancer Ther (2007) 2.01
Induction of a heat shock factor 1-dependent stress response alters the cytotoxic activity of hsp90-binding agents. Clin Cancer Res (2000) 1.81
Hsp90 and Cdc37 -- a chaperone cancer conspiracy. Curr Opin Genet Dev (2005) 1.78
Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells. J Pharmacol Exp Ther (2011) 1.77
Targeting heat shock response to sensitize cancer cells to proteasome and Hsp90 inhibitors. Cancer Res (2006) 1.64
Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis. BMC Gastroenterol (2003) 1.55
Up-regulation of heat shock protein 27 induces resistance to 17-allylamino-demethoxygeldanamycin through a glutathione-mediated mechanism. Cancer Res (2006) 1.42
Epidermal growth factor receptor expression and gene copy number in conventional hepatocellular carcinoma. Am J Clin Pathol (2008) 1.41
Molecular mechanism of inhibition of the human protein complex Hsp90-Cdc37, a kinome chaperone-cochaperone, by triterpene celastrol. Angew Chem Int Ed Engl (2009) 1.34
Targeting the oncogene and kinome chaperone CDC37. Nat Rev Cancer (2008) 1.32
Cyclins and cyclin-dependent kinases: comparative study of hepatocellular carcinoma versus cirrhosis. Hepatology (2003) 1.31
Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells. J Hepatol (2012) 1.28
Targeted therapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol (2009) 1.27
Differential gene expression in anaplastic lymphoma kinase-positive and anaplastic lymphoma kinase-negative anaplastic large cell lymphomas. Hum Pathol (2005) 1.26
Silencing the cochaperone CDC37 destabilizes kinase clients and sensitizes cancer cells to HSP90 inhibitors. Oncogene (2008) 1.24
Functional dissection of cdc37: characterization of domain structure and amino acid residues critical for protein kinase binding. Biochemistry (2003) 1.21
Targeting Cdc37 inhibits multiple signaling pathways and induces growth arrest in prostate cancer cells. Cancer Res (2007) 1.19
Small molecule antagonists of Tcf4/beta-catenin complex inhibit the growth of HCC cells in vitro and in vivo. Int J Cancer (2010) 1.19
Induction of human Cdc37 in prostate cancer correlates with the ability of targeted Cdc37 expression to promote prostatic hyperplasia. Oncogene (2000) 1.13
AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC). J Hepatol (2009) 1.12
Suppression of glypican 3 inhibits growth of hepatocellular carcinoma cells through up-regulation of TGF-β2. Neoplasia (2011) 1.09
Role of HSP90, CDC37, and CRM1 as modulators of P16(INK4A) activity in rat liver carcinogenesis and human liver cancer. Hepatology (2005) 1.09
Changes in apoptosis-related pathways in acute myelocytic leukemia. Cancer Genet Cytogenet (2003) 1.01
AZD6244 (ARRY-142886) enhances the antitumor activity of rapamycin in mouse models of human hepatocellular carcinoma. Cancer (2010) 0.94
Cdc37 enhances proliferation and is necessary for normal human prostate epithelial cell survival. Cancer Res (2003) 0.92
Genome-wide functional screening identifies CDC37 as a crucial HSP90-cofactor for KIT oncogenic expression in gastrointestinal stromal tumors. Oncogene (2013) 0.86
Cyclin D1 overexpression is not a specific grouping marker, but may collaborate with CDC37 in myeloma cells. Int J Oncol (2004) 0.84
An enzymatic method for the consistent production of monodispersed viable cell suspensions from human solid tumors. J Surg Oncol (1985) 0.79
Blocking the chaperone kinome pathway: mechanistic insights into a novel dual inhibition approach for supra-additive suppression of malignant tumors. Biochem Biophys Res Commun (2010) 0.79